Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Robinson

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Journal of Gastroenterology|December 24, 2013
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
Inflammatory Intestinal Diseases|September 18, 2018
Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance TherapySatoshi Motoya, Mamoru Watanabe, Kori Wallace, et al.
Journal of Crohn'S & Colitis|June 26, 2018
Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2Frank M Ruemmele, Joel Rosh, William A Faubion, et al.
The American Journal of Gastroenterology|June 6, 2018
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid RegistryGeert DʼHaens, Walter Reinisch, Remo Panaccione, et al.
Journal of Crohn'S & Colitis|November 6, 2016
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND TrialWalter Reinisch, Jean-Frédéric Colombel, Geert D'Haens, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 17, 2013
Adalimumab induces deep remission in patients with Crohn's diseaseJean-Frédéric Colombel, Paul J Rutgeerts, William J Sandborn, et al.
Inflammatory Bowel Diseases|April 19, 2018
Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND DataBrian Feagan, William J Sandborn, Paul Rutgeerts, et al.
Inflammatory Bowel Diseases|January 28, 2017
Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's DiseaseWilliam A Faubion, Marla Dubinsky, Frank M Ruemmele, et al.
Therapeutic Advances in Gastroenterology|August 1, 2020
Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trialBaili Chen, Xiang Gao, Jie Zhong, et al.
Inflammatory Bowel Diseases|September 2, 2016
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel DiseasesSubrata Ghosh, William J Sandborn, Jean-Frederic Colombel, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Journal of Gastroenterology|December 24, 2013
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
Inflammatory Intestinal Diseases|September 18, 2018
Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance TherapySatoshi Motoya, Mamoru Watanabe, Kori Wallace, et al.
Journal of Crohn'S & Colitis|June 26, 2018
Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2Frank M Ruemmele, Joel Rosh, William A Faubion, et al.
The American Journal of Gastroenterology|June 6, 2018
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid RegistryGeert DʼHaens, Walter Reinisch, Remo Panaccione, et al.
Journal of Crohn'S & Colitis|November 6, 2016
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND TrialWalter Reinisch, Jean-Frédéric Colombel, Geert D'Haens, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 17, 2013
Adalimumab induces deep remission in patients with Crohn's diseaseJean-Frédéric Colombel, Paul J Rutgeerts, William J Sandborn, et al.
Inflammatory Bowel Diseases|April 19, 2018
Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND DataBrian Feagan, William J Sandborn, Paul Rutgeerts, et al.
Inflammatory Bowel Diseases|January 28, 2017
Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's DiseaseWilliam A Faubion, Marla Dubinsky, Frank M Ruemmele, et al.
Therapeutic Advances in Gastroenterology|August 1, 2020
Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trialBaili Chen, Xiang Gao, Jie Zhong, et al.
Inflammatory Bowel Diseases|September 2, 2016
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel DiseasesSubrata Ghosh, William J Sandborn, Jean-Frederic Colombel, et al.
Pageof 5